TheraRadar
← Back
Data updated: May 30, 2026

SHIONOGI

Specialty
Infectious DiseaseMetabolicGastroenterology Execution: Excellent

SHIONOGI is a specialty pharmaceutical company focused on Infectious Disease, Metabolic, Gastroenterology. Key products include FETROJA.

1993
Since
10
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
2 Small Molecules

FDA Novel Drug Designations

(2017-2019)
2 Novel 1 First-in-Class 1 Orphan 1 Priority Review 1 Fast Track
See 2 novel approvals →
2019 FETROJA (CEFIDEROCOL SULFATE TOSYLATE) Priority Review · Fast Track
2017 RADICAVA (EDARAVONE) First-in-Class · Orphan

SHIONOGI at a Glance

  • Strong track record with 82% execution quality across 59 trials
  • Fast trial execution (12 months median completion)

SHIONOGI's Key Drugs

SHIONOGI's core commercial portfolio centers on FETROJA, RADICAVA ORS, spanning Infectious Disease and Metabolic — its most strategically important drugs approved in the last 15 years.

FETROJA
Infectious Disease

Complicated Urinary Tract Infection

Approved 2019
RADICAVA ORS
CNS

Amyotrophic Lateral Sclerosis

Approved 2022

SHIONOGI's Recent FDA Approvals

New NDA/BLA approvals for SHIONOGI over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

SHIONOGI's Therapeutic Areas

SHIONOGI's approved drugs and pipeline span 5 therapeutic areas, led by Infectious Disease and Metabolic, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 60%
1 drugs Phase 3: 3 Phase 2: 5 Phase 1: 1
Metabolic 23%
0 drugs Phase 2: 4 Phase 1: 3
Gastroenterology 8%
0 drugs Phase 2: 1 Phase 1: 2
Oncology 4%
0 drugs Phase 1: 2
Dermatology 4%
0 drugs Phase 2: 1

SHIONOGI's Top Competitors

SHIONOGI's closest competitors by therapeutic-area and drug-target overlap include Baxter, Johnson & Johnson, and Pfizer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Baxter specialty
Infectious Disease, Oncology, Dermatology, Metabolic
Johnson & Johnson big-pharma
Oncology, Infectious Disease, Gastroenterology, Metabolic
Pfizer big-pharma
Oncology, Infectious Disease, Dermatology
KING PHARMS big-pharma
Oncology, Metabolic, Infectious Disease, Dermatology
Merck big-pharma
Oncology, Infectious Disease, Metabolic

SHIONOGI Pipeline Snapshot

SHIONOGI has 22 active clinical programs from ClinicalTrials.gov — 3 Phase 3, 11 Phase 2 and 8 Phase 1.

3
Phase 3
11
Phase 2
8
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • FETROJA leads revenue
  • • 2 key drugs tracked

Trial Catalysts

  • • Infectious Disease pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 15/16 completed
  • • Speed: 12 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges